You have a body-composition printout, the fat number has fallen and so has the lean number, and nobody has told you which of those two facts matters.

The standard advice at this point is to eat more protein. That advice is correct and it is not a decision. The decision is whether the lean-mass figure in front of you represents actual muscle, whether the fraction it makes up of your total loss is within the range the trial literature considers ordinary, and what specifically should change if it is not.

This piece covers what the number is made of, what the fraction looks like across different methods of losing weight, and the honest position on where the threshold for acting sits, which is that no validated one exists for adults in this age band.

Older adults and sarcopenic obesity are a separate clinical problem with its own diagnostic criteria and its own literature, covered in obesity after 65 rather than here.

Key Takeaways:

• The quarter rule is an arithmetic model, not a measured threshold. It was never validated as a line an individual crosses, and no guideline sets a specific fat-free-mass fraction that should trigger a change of plan.
• Lean soft tissue on a DXA scan is not muscle. It includes glycogen, water, organs and connective tissue. An early lean-mass fall in the first two to four weeks of a deficit is more likely to reflect glycogen and water loss than actual muscle wasting.
• In the tirzepatide DXA substudy within SURMOUNT-1, the fat-to-lean split was approximately 75/25, the same proportion as placebo despite much larger absolute losses.
• Indian adults start with less appendicular skeletal muscle mass at the same BMI than European populations. The same absolute lean-mass loss therefore costs proportionally more from a smaller reserve.
• Two interventions reliably reduce the lean fraction: higher protein intake (at least 1.2 g/kg/day in diet studies) and resistance training. Combined, they can preserve or even increase lean mass while fat mass falls.

Almost every conversation about muscle loss during dieting rests on a single figure: about one quarter of the weight lost is fat-free mass, and the other three quarters is fat. It is worth knowing where that came from, because its origin explains its limits.

Heymsfield and colleagues traced the rule in a 2014 critical review back to modelling work by Grande and by Forbes on the energy content and tissue composition of weight change. The reconstruction showed that the ratio is not an empirical observation so much as an arithmetic consequence: plug average energy densities of fat and fat-free mass into a two-compartment model, assume excess weight is about 22% lean and 78% fat, and a fat-free mass fraction of roughly 0.25 falls out of the equation.

That matters because a number derived this way behaves differently from one measured directly. The fraction of weight lost as fat-free mass is dynamic. It runs higher in the first days and weeks of an energy deficit and settles lower as dieting continues, and it is substantially modified by age, inactivity and exercise.

In pooled low-calorie diet studies summarised in that review, six-month protocols in adults starting around 100 kg produced fat-free mass losses of roughly 1 to 3 kg against total losses of around 10 kg, consistent with the rule but with wide variation by regimen and by measurement method.

So the quarter rule is a reasonable expectation and a poor threshold. It describes a central tendency across populations. It was never validated as a line that an individual crosses.

This is the part that changes how the printout should be read, and it is a measurement fact rather than a clinical opinion.

In almost all the trials referenced in this article, lean mass is measured by dual-energy X-ray absorptiometry, which partitions the body into bone mineral, fat mass and lean soft tissue. Lean soft tissue is not muscle. It includes:

• Skeletal muscle
• Organs (including the liver)
• Connective tissue
• Glycogen and the water bound to it
• Extracellular water

A fall in the lean-tissue compartment can reflect any of the above, none of which is loss of contractile muscle protein.

Two further limitations compound this:

• DXA measures two tissue types at a time, so hydration changes between scans confound the lean estimate directly.
• Fat-free mass losses in weight-loss trials are typically small enough to sit near the limits of the method's reliability.

The practical reading follows from that. A drop of one to three kilograms of lean mass in the first fortnight of a new deficit, particularly in a younger and physically active person, is more likely to be glycogen and water than muscle wasting, and should not be treated as the latter unless strength or performance is falling alongside it.

Repeated measurements over three to six months, read together with functional tests such as grip strength, chair rises and gait speed, give a picture that a single scan cannot.

Imaging that is more specific to muscle supports this. MRI-based body-composition analysis can quantify muscle volume and fat infiltration separately, and where it has been applied in weight-loss trials it has found muscle volume better preserved than DXA lean-mass figures suggested.

Which method a given trial used is therefore not a technical footnote. It determines what its numbers mean. Device selection, precision, least significant change and the validity of consumer body-composition scales are dealt with in comparing body-composition methods rather than here.

Read across the literature and the fraction of weight lost as lean mass clusters, with the spread explained largely by protein intake, training and how the measurement was taken.

Energy restriction alone

Around 20 to 30% of weight lost was lean mass. A systematic review and meta-analysis in adults aged 50 and over found that roughly 25% of body mass lost was lean mass, based on DXA, air-displacement plethysmography, hydrostatic weighing or tracer methods.

Severe versus moderate restriction

Lean-mass loss remained proportional rather than becoming worse with more severe restriction. In a 12-month trial in postmenopausal women, severe restriction of 65 to 75% produced about twice the weight and fat loss and around 1.5 times the lean-mass loss of moderate restriction of 25 to 35%. However, the losses remained proportional to total weight loss, and handgrip strength did not differ between the groups.

Rapid versus gradual weight loss

Rapid weight loss resulted in greater early lean-mass loss. A double-blind trial randomised 42 adults to lose at least 5% of their weight over either five weeks or fifteen weeks. Gradual weight loss produced greater reductions in fat mass and body-fat percentage, while rapid weight loss produced larger reductions in lean body mass, fat-free mass and total body water.

Very-low-calorie diets

Lean mass accounted for around 25% of total weight loss. A sports-nutrition position stand notes that even with protein intake as low as 50 g per day, lean loss from formula diets below 800 kcal per day has often been reported at about one quarter of total weight loss.

Bariatric surgery

Lean-mass loss was often below 25% of total weight loss. In a DXA cohort of 41 women after Roux-en-Y gastric bypass, fat mass continued to fall while lean mass decreased moderately during the first three months and then stabilised. A meta-analysis of randomised trials also found similar lean-mass loss across procedures despite differences in total weight loss.

Two things stand out. First, severity and speed mostly scale the absolute lean loss rather than the fraction, within the ranges studied. Second, in the one trial that measured both, the group that lost more lean mass did not end up weaker, which is the clearest single argument for not treating a lean-mass number as a verdict on its own.

Several body-composition substudies now exist within pharmacotherapy trials. They are reported here for one reason only, which is that they are where the most precise measurement of the fat-to-lean split currently sits. Nothing in this section describes who should take a medicine, and none of these figures is a reason to start one. Prescribing decisions for any of these drugs are made by a registered medical practitioner after an individual assessment, and the medicines named are prescription-only.

The clearest dataset is the DXA substudy within SURMOUNT-1, which enrolled 160 participants with baseline and week-72 scans. In that substudy, tirzepatide reduced body weight by 21.3%, fat mass by 33.9% and lean mass by 10.9%, against 5.3%, 8.2% and 2.6% on placebo.

Post-hoc analysis put the split at approximately 75% fat and 25% lean, essentially identical in proportion to placebo despite the much larger absolute losses.

Three labelling points belong with that figure:

• The 21.3% is the substudy's own figure, not the trial's headline. SURMOUNT-1 reported 20.9% on the treatment-regimen estimand and 22.5% on the efficacy estimand, so any figure cited must state which one it represents.
• The dose mix and estimand within the DXA subgroup are not specified in the research behind this article, so the 21.3% cannot be mapped onto either headline figure.
• "Lean mass" here is DXA lean soft tissue, which includes glycogen and water. The apparent lean loss probably overstates true muscle loss, particularly early in treatment.

The semaglutide data are less consistent. STEP 1, which studied once-weekly semaglutide 2.4 mg plus lifestyle intervention over 68 weeks, reported mean weight loss of 14.9% against 2.4% on placebo. The DXA subpopulation of 140 participants showed reductions in total and visceral fat mass and a fall in absolute lean body mass in kilograms, alongside an increase in lean mass as a proportion of total body mass.

Secondary analyses put lean mass at roughly one third to two fifths of total weight lost in STEP 1, higher than the tirzepatide figure, though the reported percentage varies by estimand and subgroup.

Two further datasets circulate in this area, from the STEP UP and REDEFINE 1 trials. Both reach the research behind this article only through congress presentations hosted by the manufacturer rather than peer-reviewed papers, and neither arrives with the dose and duration attached that would make its figure interpretable. They are named here so a reader who encounters them knows they exist, and left out of the comparison for that reason.

Set side by side, the two peer-reviewed substudies put lean loss at roughly a quarter to two fifths of weight lost, and the spread is driven at least as much by imaging modality and body region measured as by the drug. That range brackets the quarter rule rather than overturning it.

This is the finding that narrows the margin, and it is specific to the population this article is written for.

Cross-ethnic DXA work comparing 933 adults across European, Maori, Pacific Island and Asian Indian groups derived appendicular skeletal muscle mass from limb scans and found that Asian Indians had the lowest of the four groups, both before and after adjustment for age, height and weight.

The same body of work found predicted body-fat percentage at a BMI of 30 kg/m²:

European: approximately 29% body fat in men. The figure for women was not reported.

• Pacific: approximately 25% in men and 38% in women.
• Asian Indian: approximately 37% in men and 47% in women.

Asian Indians carry significantly more fat at the same BMI.

The implication for this topic is arithmetic rather than dramatic. An Indian adult beginning a weight-loss intervention typically starts with more fat and less muscle at the same BMI than the populations most of the trial literature was conducted in. The same absolute loss of lean mass therefore consumes a larger share of the reserve available. The tolerable margin is narrower, which is an argument for adopting muscle-protective measures early rather than waiting for a number to look alarming.

One honest limit belongs here. Indian consensus documents that reflect this lower baseline in ethnicity-specific skeletal-muscle-index cut-offs were written for sarcopenia in older adults. Good DXA-derived reference values for skeletal muscle index in Indian adults aged 25 to 55 were not identified in the research behind this article, so there is no Indian normal range against which to read a younger adult's result.

The quarter rule is not fixed, and two interventions move it reliably.

Protein first. What the evidence shows:

• A systematic review in older adults found that higher-protein diets (at least 25% of energy or 1.2 g/kg/day) preserved more lean mass and produced greater fat loss than standard intakes, without changing total weight loss.
• In a two-week 40% energy restriction study, protein at about 2.3 g/kg/day produced only 0.3 kg of lean loss against 1.6 kg at 1.0 g/kg/day, for a similar total weight loss.
• Sports-nutrition guidance suggests 2.3 to 3.1 g/kg of fat-free mass for lean, resistance-trained athletes in a deficit. This is a specialised population, not a general recommendation.
• Protein targets in anyone with kidney disease are set by nephrology and run in the opposite direction.

Loading second, and the effect is larger than most people expect. A short experiment used an extreme energy deficit alongside extensive low-intensity exercise:

• Legs and an exercised arm lost 57% and 29% less fat-free mass than a non-exercised arm in the same person.
• Protein alone (0.8 g/kg/day at that deficit) did not prevent lean loss.
• Local muscle use protected local muscle even while whole-body fat-free mass was falling.

Combined approaches can invert the expected direction entirely:

• In a trial pairing high-intensity exercise with protein at 2.4 g/kg/day, participants gained 1.2 kg of lean mass while losing 4.8 kg of fat.
• The 1.2 g/kg/day comparison arm held lean mass roughly steady with smaller fat loss.
• In premenopausal women across resistance training, diet, both, or control: every group reduced fat mass, but only the resistance-training-only group significantly increased lean mass.

Here is the part that is usually asserted with more confidence than the evidence supports, so it is worth being exact about what is known.

No randomised trial has prospectively tested "stop or modify weight loss when fat-free mass loss exceeds 25% of total weight loss" as a clinical rule. To be specific about what is absent:

• The Forbes-derived 22% lean figure is a modelling inference, not a clinical standard.
• No published pharmacotherapy threshold exists beyond which weight loss is deemed too costly to lean tissue.
• No Indian guideline for adults aged 25 to 55 sets a functional threshold such as a percentage fall in grip strength that should prompt a change of plan.

What can be said, on trial-level patterns rather than on a validated rule, is what a clinician is reading for:

• Two measurements, not one: A single scan cannot separate glycogen and water shift from muscle loss. Repeated composition measures over three to six months, taken on the same method, are what make a trend interpretable.
• Composition and function together: A lean-mass fall accompanied by declining grip strength, chair-rise performance or endurance is a different finding from the same fall with stable or improving strength. In the trials where both were measured, function frequently held while lean mass dropped.
• The fraction, read against the method: Fractions around a quarter are ordinary across diet, formula-diet and drug-treated weight loss. Fractions well above that, in the 35 to 40% range, appear in the literature where protein is low and activity is absent, which points at the plan rather than at the person.
• A narrower margin in Indian adults: Lower appendicular skeletal muscle mass at a given BMI means the same absolute loss costs proportionally more, so the case for early protein and resistance work is stronger than the trial averages alone imply.

When those readings do point to a change, the change is to the plan and not to the goal: a slower rate of loss, higher protein where kidney function permits it, and structured resistance work.

That is a clinical judgement made against your own baseline and your own results, which is exactly the class of decision that does not survive being made from a printout alone. The gap between a plan that adjusts on measurement and one that adjusts on the calendar is the subject of what a programme does, and it is worth reading before deciding how yours is being run.

A lean-mass reading you are not sure how to interpret? A Voy clinician can put it alongside your baseline and your plan. Book an assessment.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.